

**GYNECOLOGIC ONCOLOGY PROTOCOLS
STUDIES LISTED ARE OPEN**

5/15/206

OVARIAN

- GOG #136: Acquisition of Human Ovarian and Other Tissue Specimens and Serum to be used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer; Activated 8/10/92
All stages Includes all epithelial tumors, germ cell, sex cord stromal and other primary ov malignancies
- GOG#146Q: A Randomized Phase II Evaluation of Topotecan Administered Daily X 5 every 3 weeks VS weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Rec **(Treatment free interval without progression following a response greater than 6 and less than 12 months only)**
- GOG #175: A Randomized Phase III Trial of IV Carboplatin and Paclitaxel X 3 courses plus low dose Paclitaxel weekly versus IV Carboplatin and Taxol in Patients with Early Stage Ovca
Stage I/II
- GOG #190: An Exploratory Evaluation of Fenretinide (4-HPR) (IND #39,812) As a Chemopreventive agent for Ovarian Carcinoma
- GOG #198: A Randomized Study of Tamoxifen versus Thalidomide in Patients with Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma after First Line Chemotherapy
Rec
- GOG #212: A Randomized Phase III Trial of Maintenance Chemotherapy comparing 12 monthly cycles of Single Agent Paclitaxel or Xyotax versus no treatment until documented relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Achieve a complete clinical response to primary Platinum/Taxane Chemotherapy
- GOG #218: A Phase III Trial of Carboplatin and Paclitaxel plus Placebo versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab followed by placebo, versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated suboptimal advanced stage Epithelial Ovarian and Primary Peritoneal Cancer
- Genentech: A Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Pertuzumab (rhuMAb 2C4) in Combination with Gemcitabine and the Effect of Tumor-Based HER2 Activation in Subjects with Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
- GOG#9915 Modesitt: A Phase I Study using Low Dose Abdominal Radiotherapy as a Taxotere Chemosensitizer for Recurrent/Persistent or Advanced Ovarian Cancer (Radiation Medicine 3-6486)

89-GYN-19: The Efficacy of Transvaginal Sonography in Determining the Size and Morphology of Ovaries in Patients with Nonadenexal Disease

2002-GYN-01: Ovarian Minimally Invasive Diagnostics (MID)

DePriest: Correlation of Serum CA-125 and Soluble EGRF versus Intracyclic CA-125 and Soluble EGRF

TROPHOBLASTIC DISEASE

GOG #174: A Randomized Phase III Trial of Weekly Parenteral Methotrexate versus “Pulsed” Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia

CERVICAL

GOG #204: Randomized Phase III Trial of Paclitaxel plus Cisplatin versus Vinorelbine plus Cisplatin versus Gemcitabine plus Cisplatin versus Topotecan plus Cisplatin in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
IVB,Rec
Pers

VULVAR

GOG #205: A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Primary Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva
Advanced

ENDOMETRIAL

GOG #209: Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial

SARCOMA

No protocols at this time.